
Subarachnoid Hemorrhage- Pipeline Insight, 2024
Description
Subarachnoid Hemorrhage- Pipeline Insight, 2024
DelveInsight’s, “Subarachnoid Hemorrhage- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Subarachnoid Hemorrhage pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Subarachnoid Hemorrhage: Overview
A subarachnoid hemorrhage means that there is bleeding in the space that surrounds the brain. Most often, it occurs when a weak area in a blood vessel (aneurysm) on the surface of the brain bursts and leaks. The blood then builds up around the brain and inside the skull increasing pressure on the brain. This can cause brain cell damage, life-long complications, and disabilities. A subarachnoid hemorrhage may occur as a complication of a type of stroke called a hemorrhagic stroke, or bleeding inside the brain. This is different from an ischemic stroke, which is caused by a blood clot. This bleeding can sometimes cut through the brain tissue and leak into the area outside the brain (called the subarachnoid space). This is called a subarachnoid hemorrhage and can be life threatening. The blood from the hemorrhage can compress or displace vital brain tissue. A severe hemorrhage can cause a coma, or leave the patient paralyzed. Common symptoms of a subarachnoid hemorrhage include: Loss of consciousness, double vision, nausea or vomiting, severe headache, trouble speaking, drooping eyelid, confusion and trouble concentrating. If patient have symptoms of a subarachnoid hemorrhage, a doctor might use several tests to diagnose it: MRI scan. This test uses large magnets, radiofrequency energy, and a computer to make detailed images of the brain. CT scan-This test uses X-rays and computer technology to make horizontal, or axial images (often called slices) of the brain. CT scans are more detailed than general X-rays. Angiogram-During this test, dye is injected in the blood vessel and then X-rays are taken to evaluate blood flow through them. Spinal tap-In this test, a special needle is placed into the lower back, into the spinal canal. The pressure in the spinal canal and brain can be measured. A small amount of cerebrospinal fluid can be removed and analyzed for the presence of blood. A diagnosis of a cerebral aneurysm isn't usually made until a subarachnoid hemorrhage has already occurred. A subarachnoid hemorrhage is a medical emergency. Immediate treatment is essential to help reduce the risk for permanent brain damage. The main goal of treating a subarachnoid hemorrhage is to stop the bleeding. Often, a doctor may do surgery to place a small clip on the blood vessel to stop blood from leaking into the brain. After a subarachnoid hemorrhage, serious complications can occur. Swelling in the brain, or hydrocephalus, is one of the potential complications. This is caused by the buildup of cerebrospinal fluid and blood between the brain and skull, which can increase the pressure on the brain. Subarachnoid hemorrhage can also irritate and damage the brain's other blood vessels, causing them to tighten—this reduces blood flow to the brain. As blood flow becomes affected, another stroke can result, leading to even further brain damage. In serious cases, the bleeding may cause permanent brain damage, paralysis, or coma.
""Subarachnoid Hemorrhage- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Subarachnoid Hemorrhage pipeline landscape is provided which includes the disease overview and Subarachnoid Hemorrhage treatment guidelines. The assessment part of the report embraces, in depth Subarachnoid Hemorrhage commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Subarachnoid Hemorrhage collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Subarachnoid Hemorrhage R&D. The therapies under development are focused on novel approaches to treat/improve Subarachnoid Hemorrhage.
This segment of the Subarachnoid Hemorrhage report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Subarachnoid Hemorrhage Emerging Drugs
- Nicardipine: BIT Pharma GmbH
- GTX 104: Acasti Pharma
- NP 10679: NeurOp
Further product details are provided in the report……..
Subarachnoid Hemorrhage: Therapeutic Assessment
This segment of the report provides insights about the different Subarachnoid Hemorrhage drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Subarachnoid Hemorrhage
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Subarachnoid Hemorrhage: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Subarachnoid Hemorrhage therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Subarachnoid Hemorrhage drugs.
Subarachnoid Hemorrhage Report Insights
- Subarachnoid Hemorrhage Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Subarachnoid Hemorrhage drugs?
- How many Subarachnoid Hemorrhage drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Subarachnoid Hemorrhage?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Subarachnoid Hemorrhage therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Subarachnoid Hemorrhage and their status?
- What are the key designations that have been granted to the emerging drugs?
- BIT Pharma GmbH
- Acasti Pharma
- NeurOp
- CSL Behring
- Avilex Pharma
- Carlsson Research AB
- GTX 104
- Nicardipine
- NP 10679
- CSL 888
- AVLX-144
- OSU 6162
- Dexmedetomidine
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Subarachnoid Hemorrhage: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Subarachnoid Hemorrhage– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Nicardipine: BIT Pharma GmbH
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- NP 10679: NeurOp
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Subarachnoid Hemorrhage Key Companies
- Subarachnoid Hemorrhage Key Products
- Subarachnoid Hemorrhage- Unmet Needs
- Subarachnoid Hemorrhage- Market Drivers and Barriers
- Subarachnoid Hemorrhage- Future Perspectives and Conclusion
- Subarachnoid Hemorrhage Analyst Views
- Subarachnoid Hemorrhage Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.